Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Long-Term Investments (2016 - 2023)

Sangamo Therapeutics (SGMO) has disclosed Long-Term Investments for 12 consecutive years, with $39.0 million as the latest value for Q2 2023.

  • For Q2 2023, Long-Term Investments fell 18.62% year-over-year to $39.0 million; the TTM value through Jun 2023 reached $39.0 million, down 18.62%, while the annual FY2022 figure was $29.8 million, 66.15% down from the prior year.
  • Long-Term Investments hit $39.0 million in Q2 2023 for Sangamo Therapeutics, up from $35.6 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $95.6 million in Q3 2021 and bottomed at $5.0 million in Q1 2020.
  • Average Long-Term Investments over 5 years is $45.7 million, with a median of $44.1 million recorded in 2020.
  • Year-over-year, Long-Term Investments crashed 75.28% in 2019 and then surged 748.62% in 2021.
  • Sangamo Therapeutics' Long-Term Investments stood at $21.8 million in 2019, then soared by 131.45% to $50.5 million in 2020, then skyrocketed by 74.49% to $88.2 million in 2021, then crashed by 66.15% to $29.8 million in 2022, then skyrocketed by 30.8% to $39.0 million in 2023.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $39.0 million, $35.6 million, and $29.8 million for Q2 2023, Q1 2023, and Q4 2022 respectively.